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Background: A study was designed to identify the source of fever in a patient with post-polycythemia myelofibrosis,
associated with clonal Janus Kinase 2 (JAK2) mutation involving duplication of exon 12. The patient presented with 1–2 day
long self-limited periodic episodes of high fever that became more frequent as the hematologic disease progressed.
Methods: After ruling out other causes for recurrent fever, analysis of the pyrin encoding Mediterranean fever gene (MEFV)
was carried out by Sanger sequencing in peripheral blood DNA samples obtained 4 years apart, in buccal cells, laser
dissected kidney tubular cells, and FACS-sorted CD3-positive or depleted mononucleated blood cells.
Hematopoeitc cells results were validated by targeted deep sequencing. A Sanger sequence based screen for
pathogenic variants of the autoinflammatory genes NLRP3, TNFRSF1A and MVK was also performed.
Results: A rare, c.1955G>A, p.Arg652His MEFV gene variant was identified at negligible levels in an early peripheral blood
DNA sample, but affected 46 % of the MEFV alleles and was restricted to JAK2-positive, polymorphonuclear and
CD3-depleted mononunuclear DNA samples obtained 4 years later, when the patient experienced fever bouts. The
patient was also heterozygous for the germ line, non-pathogenic NLRP3 gene variant, p.Q705K. Upon the administration
of colchicine, the gold standard treatment for familial Mediterranean fever (FMF), the fever attacks subsided.
Conclusions: This is the first report of non-transmitted, acquired FMF, associated with a JAK2 driven clonal expansion of
a somatic MEFV exon 10 mutation. The non-pathogenic germ line NLRP3 p.Q705K mutation possibly played a
modifier role on the disease phenotype.
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Polycythemia vera (PV; MIM 263330) is a clonal pro-
gressive myeloproliferative disorder primarily character-
ized by elevation in red blood cells, often with increased
myeloid elements. The major pathogenic event in PV is
the acquisition of a somatic gain-of-function mutation in
the Janus Kinase 2 gene (JAK2; MIM 147796), resulting* Correspondence: Ophira.Salomon@sheba.health.gov.il
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creativecommons.org/publicdomain/zero/1.0/in erythropoietin independent proliferation of erythroid
progenitor cells. Approximately 96 % of PV cases involve
the p.V617F mutation in exon 14 of JAK2 [1], while 3 %
involve exon 12, with 37 different mutations described
to date [2–5]. Transformation into myelofibrosis and
acute leukemia occurs in 10 and <3 % of the patients, re-
spectively, during a 10-year disease course [1].
The Mediterranean fever gene (MEFV; MIM 608107) is
highly expressed in myeloid cells, particularly in mature
granulocytes. This gene codes for pyrin, a cytoplasmatic
protein that regulates the maturation and secretion of the
proinflammatory cytokines IL-1b and IL-18 in theticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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MEFV associate with familial Mediterranean fever (FMF;
MIM 249100), an autoinflammatory and inherited disorder
prevalent in Mediterranean descendants. FMF is character-
ized by 2–3 days long self-limited attacks of fever, abdom-
inal pain, arthritis and /or pleuritis [10]. The attacks are
accompanied by leukocytosis and neutrophil infiltration to
synovial membranes. Colchicine is the gold standard treat-
ment for FMF, and is of diagnostic value. Biallelic MEFV
exon 10 mutations are detected in 50–60 % of FMF pa-
tients. In 10–20 % of patients a monoallelic mutation is
found, usually manifested with mild symptoms [11–15]. A
gain-of-function, leading to an increase in the maturation
of proinflammatory cytokines to their secreted forms, was
suggested to explain the pathogenicity of these conservative
missense MEFV mutations [8, 9]. A case of transmission of
FMF by bone marrow transplantation from a donor with
undiagnosed FMF proved the disease could be acquired
throughMEFV mutated hematopoietic cells [16].
Herein, we present for the first time genetic evidence for
naturally acquired FMF, in a middle aged patient who had
post-PV myelofibrosis. The patient developed FMF, while
a negligible, myeloid restricted somatic MEFV exon 10
mutation increased in its mosaicism level. Co-segregation
into myeloid cells with a JAK2 mutation with growth ad-
vantage suggests that the MEFV mutation was a hitch-
hiker during clonal expansion.
Methods
Patient
The patient is a 59 years old Ashkenazi Jewish female di-
agnosed with PV at 52 years, and followed at the Sheba
Medical Center, Tel Hashomer, IL. Genetic testing for the
JAK2 p.V617F mutation was negative but sequencing of
exon 12 revealed the NM_004972.3:c.1608_1640dup
variant, known as F537-I546dup+F546L on the protein
level [3] and designated p.(Ile546_Phe547insLeuPheHi
sLysIleArgAsnGluAspLeuIle) according to HGVS no-
menclature. This duplication predicts a substitution in
the p.Phe547 hotspot residue followed by insertion of ten
amino acids in the SH2 linker and pseudokinase JH2 do-
main. The patient has been treated with phlebotomies
when needed and with100 mg acetylsalicylate daily. Four
years later the patient’s spleen enlarged dramatically
reaching 20 cm and a bone marrow biopsy confirmed
transformation into myelofibrosis according to the inter-
national working group for myelofibrosis [17]. At that
time, the patient developed fever bouts, initially reaching
38 °C and lasting 24 h, at 2 months intervals and a year
after occurring at shorter intervals, rising to 39 °C and
lasting up to 48 h with occasional abdominal pain and/or
muscle aches. The C-reactive protein was elevated during
fever, reaching 19 mg/L (normal levels <0.08–5 mg/L). Ex-
tensive work up for fever of unknown origin failed todetect infection, malignancy, collagen disease or throm-
botic events. Clinical diagnosis of FMF was then consid-
ered. Surprisingly, a rare mutation in the MEFV gene was
detected and daily treatments with 1 mg colchicine abated
the fever. A recent development of mild renal failure with
moderate proteinuria led us to perform a kidney biopsy.
Samples
Polymorphonuclear (PMC) and mononuclear cells (PBMC)
were isolated by density gradient centrifugation using
Histopaque 1077 (Sigma-Aldrich, St. Louis, MO), yielding
a pellet of PMC and a PBMC cell band at the Histopaque/
plasma interphase. Genomic DNA was prepared from
whole and isolated fractions of peripheral blood cells
(PBC), and from buccal cells using a commercially available
kit (iNtRON biotechnology, Kyungki-Do, Korea). Genomic
DNA from kidney tubule cells was purified with a column-
based method (QIAamp® DNA Micro Kit; Qiagen). This
study was approved by the ethics committee at the Sheba
Medical Center, and was performed according to the dec-
laration of Helsinki.
Genetic analyses
The JAK2 p.V617F mutation was excluded [18]. JAK2
exon 12 was PCR-amplified with flanking primers. Two
distinct gel bands on a 2 % agarose gel were excised,
purified by MinElute Gel extraction kit (QIAGEN,
Hilden, Germany) and sequenced. Amplicons of MEFV
exons 1–10 (LRG_190t1), NLRP3 exon 3 (LRG_197t1),
TNFRSF1A exons 2–4 (LRG_193t1), and MVK exons
2–11 (LRG_156t1) were sequenced after Exo-Sap treat-
ment. Sequencing reactions were performed using the
Big Dye Terminator kit (Applied Biosystems, California,
USA) on an ABI 3130XL automated sequencer, and the
sequences were analyzed with BioEdit or blast software.
For targeted deep sequencing, a first PCR reaction sur-
rounding the c.1955 nucleotide change of MEFV was
performed in triplicate. Barcodes were incorporated to
amplicons during a second, nested round of amplifica-
tion. Amplicons were then purified using Agentcourt
AMPureXP beads (Beckman coulter, Nyon, Switzerland)
and the DNA quantified using High Sensitivity DNA kits
for Bioanalyzer (Agilent technologies, Ca, USA). Sequen-
cing and analyses were performed using the 400 bp kit
on a PGM system, Ion Torrent server and Ion Reporter
software, according to manufacturer’s instructions (Ion
Torrent, Life Technologies, Guilford, Connecticut, USA).
Coverage at the c.1955 position was at least ×3000.
Restriction Site Length Polymorphism (RFLP) analysis
Exon 10 RFLP of the c.1955G>A MEFV variant was
performed with Fnu4hI enzyme (New England Biolabs,
Ipswich, MA, USA) following manufacturer’s instructions.
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PBMC were immunostained with PE-conjugated anti-CD3
(UCHT1) mAbs from BD Biosciences (San Jose, CA) for
15 min at room temperature. Two cell populations, CD3+
Tcells and CD3-depleted PBMC were sorted with high pur-
ity (>95 %) with a stringent multiparametric discrimination
algorithm, by FACSAria digital cell sorter (BD Biosciences).
Pathology
Bone marrow biopsies obtained in 2009 and 2012 showed
morphological features of myelofibrosis with increased
reticulin fibers (grade 2). Kidney biopsy showed diffuse
mesangioproliferative and focal endocapillary proliferative
glomerulonephritis. Immunofluorescence showed IgM and
C3+ granular stain without clonality. Congo red staining
was negative for amyloid.
Laser capture microdissection
Five-micrometres thick paraffin embedded kidney biopsy
sections were placed on membrane-coated slides (PALM,Fig. 1 Sanger Sequencing results of JAK2 exon 12 DNA sequence (NM_004
nutation b-c of CD3+ cells and buccal cells presenting wild type DNA sequ
is duplicated in the PBC sample and not in the CD3+ T cells or the buccalMunich, Germany), heated at 60 °C overnight and stained
with hematoxillin and eosine. Tubular cells were dissected
and catapulted onto a microfuge tube lid on a robotstage
microscope equipped with a 337-nm pulsed laser micro-
beam (PALM, Munich, Germany) with a single laser shot.
Results
The patient presented with post-PV myelofibrosis involv-
ing a rare duplication in exon 12 of JAK2 (Fig. 1a) previ-
ously described in one patient [3]. The occurrence of
recurrent fever in the absence of any known underlying
cause led us to search for MEFV gene mutations. Her
Ashkenazi origin, middle aged onset and lack of family
history of FMF were not conflicting, as these have been
previously noted [19, 20]. The NM_000243.2:c.1955G>A
mutation (rs28940581) was found in exon 10 (Fig. 2a
and 2g) predicting a p.Arg652His substitution in the
PRYSPRY domain of pyrin. In the domain 3D model, the
R652 residue localizes to the β5 strand end within sheet B.
This variant was recently reported in a patient affected by972.3). DNA sequencing a of PBC presenting the c.1608_1640dup
ence of the gene. The rectangle contains the exon 12 sequence which
cells
Fig. 2 Detection, expansion and somatic distribution of the MEFV c.1955G>A mutation demonstrated by Sanger sequencing. a PBC DNA sample of
the patient from 2009 b an earlier sample from 2005 c CD3-positive T cells, d PMC enriched fraction, e buccal cells, f kidney tubule cells. g Fnu4h1 RFLP
of MEFV exon 10 visualized on a 4 % agarose E-gel. The MEFV mutation abolishes the second of three restriction sites yielding a longer, 350 base pairs
fragment. h Small power photomicrograph demonstrating a glomerulus and tubular cells. h-a High power photomicrograph demonstrating a
desiccated tubule cell, h-b before and h-c after laser capture microdissection procedure (hematoxylin and eosin stain magnification ×400)
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FMF [22]. A somatic origin for the p.Arg652His mutation
was suggested to explain the post-PV MF associated re-
current fever. We therefore tested a DNA sample preced-
ing the onset of fever by 4 years, when a search for a JAK2
mutation was performed. In the early sample the mutated
MEFV variant was repeatedly observed at a negligible level
by Sanger sequencing (Fig. 2b) whereas the JAK2 exon 12
extra gel band was highly visible. To further characterize
the somatic origin of the MEFV mutation, we performed
cell sorting on PBMC. Both the MEFV p.Arg652His and
JAK2 exon 12 mutations were present in CD3-depleted
peripheral blood mononuclear cells and the polymorpho-
nuclear cells, but not in CD3+ T lymphocytes (Figs. 1b, 2c
and d). Of note, JAK2 mutations are reported undetectable
in T cells. Targeted deep sequencing confirmed these re-
sults showing a mutated MEFV allele frequency of 46 % in
peripheral blood and in polymorphonuclear cells, 27 % in
CD3-depleted PBMC and 0 % in CD3+ T cells. In theDNA of buccal cells neither the JAK2 nor the MEFV mu-
tations were detected (Figs. 1c and 2e).
After the control of fever with colchicine treatment for
almost a year, the patient developed heavy proteinuria
with mild renal failure requiring kidney biopsy. We ex-
pected to detect glomerulosclerosis, a known late compli-
cation of myeloproliferative disorder (MPD) or secondary
amyloid nephropathy related to FMF. Unexpectedly, the
kidney biopsy showed membranoproliferative glomerulo-
nephritis and Congo red staining was negative for amyloid.
The somatic origin and restriction of the MEFV mutation
to hematopoietic cells was then re-challenged and reaf-
firmed on single tubule cells derived from kidney biopsy
(Fig. 2f and h). These results support the somatic nature
of both JAK2 and MEFV mutations, their restriction to a
myeloid clone and an increase in the somatic MEFV mu-
tation burden associated with myelofibrosis progression.
Finally, sequencing of three other known autoinflamma-
tory genes revealed one heterozygous, non-pathogenic
Shinar et al. Orphanet Journal of Rare Diseases  (2015) 10:86 Page 5 of 6variant in the NLRP3 gene, NM_004895.4:c.2113C>A,
p.Gln705Lys (historically called Q703K). This variant was
detected in both the early and late peripheral blood DNA
samples as well as in CD3+ T cells, and was concluded to
be a germ line mutation.
Discussion
The genetic analysis of a post-PV myelofibrotic patient
clinically diagnosed with FMF [10] revealed a unique som-
atic MEFV variant which, in parallel to the development
and aggravation of FMF attacks, underwent expansion. In
addition, the patient had a known, prevalent germ line
NLRP3 variant, unrelated to a specific autoinflammatory
disease, yet reported to lead to an overactive NLRP3
inflammasome, or suggested to be a low penetrance vari-
ant, which hitherto was clinically silent [23, 24].
Several findings support a pathogenic role for the rare
somatic MEFV mutation. First, the p.Arg652His variant
was the sole variation in the coding region of the gene.
Second, the somatic variant was confined to the disease
effector cells, and third, the level of MEFV mosaicism
increased in association to the development and pro-
gressive aggravation of the FMF attacks.
On the other hand, we argue against a pathogenic role
for the germ line p.Q705K NLRP3 variant in the devel-
opment of FMF, since the patient did not have an in-
flammatory phenotype prior to the expansion of the
MEFV mutation, nor is this variant known to cause
FMF. At most, it may have up-regulated the proinflam-
matory effect of the MEFV mutation, serving as a modi-
fier gene in the myeloid cells [25].
Conceivably, the acquisition of a pathogenic mutation in
the MEFV gene in somatic cells is more frequent than
heretofore observed. It remains unnoticed however, when
present in only a few cells. Somatic expansion of theMEFV
mutation made the p.Arg652His mutation clinically visible
in our patient, and tight co-segregation supports a JAK2
driven expansion of anMEFV mutated myeloid clone, irre-
spective of the order in which the two mutations occurred.
It is possible that the magnitude of inflammation was
up-regulated in our patient by a combined effect of the
rare exon 12 JAK2 mutation and the germ line, p.Q705K
modifier variant, on the inflammasome priming via the
ERK tract [2, 25]. It may also be that in other instances
recurrent FMF fever bouts have been misclassified as
constitutional symptoms, related to the primary disease.
Myeloid restricted, non-malignant somatic mosaicism
with low and variable degree (8–27 %) has recently been
reported in the NLRP3 gene of patients with the autoin-
flammatory, variant type Schnitzler syndrome, an urticar-
ial and systemic inflammation disease with monoclonal
gammopathy [26], and in a case of cyropyrin associated
periodic syndrome (CAPS) [27]. NLRP3 mosaicism affect-
ing several tissue types is more frequently found, especiallyin NOMID/CINCA patients who test negative for a het-
erozygous germ line mutation [28, 29]. Lastly, a case of
somatic mosaicism has been reported in a patient with
Blau syndrome [30]. To the best of our knowledge the
present case is the first demonstration of a somatic MEFV
mutation, expanding the spectrum of autoinflammaory
diseases caused by somatic mosacism.
In summary, this paper highlights a diversion of nature
in the course of post-PV myelofibrosis. For such a diver-
sion to occur two concomitant events are necessary: A
proliferation driver mutation should evolve in myeloid
cells and a passenger pathogenic mutation should occur in
a gene which is normally expressed in the proliferating
clone. Whether the driver and the hitchhiker mutations
converged in our case to regulate a common pathogenic
pathway awaits further proof. The phenomenon described
herein may also elucidate the pathogenesis of recurrent
fever of unknown origin frequently detected in other
malignancies.
Conclusions
This work provides clinical and genetic evidence for a
unique pathogenic route that leads to acquired FMF. A
somatic, myeloid restricted mutation in the Mediterra-
nean fever gene of a patient with post-PV myelofibrosis
expanded from negligible to 46 % of total MEFV alleles
in peripheral blood cells, parallel to the development of
colchicine responsive inflammatory fever bouts. Co-
segregation of the MEFV and JAK2 exon 12 mutations
into myeloid cells suggests the MEFV mutation was a
passenger in a JAK2 driven proliferating clone. Other
autoinflammatory diseases may be acquired due to
somatic mutations in additional clonal myeloprolifera-
tive diseases.
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